Jadavji Laboratory



Biomedical Sciences

Southern Illinois University



Impact of dietary supplementation of one-carbon metabolism on neural recovery


Journal article


Joshua T. Emmerson, Lauren K. Murray, N. Jadavji
Neural Regeneration Research, 2017

Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Emmerson, J. T., Murray, L. K., & Jadavji, N. (2017). Impact of dietary supplementation of one-carbon metabolism on neural recovery. Neural Regeneration Research.


Chicago/Turabian   Click to copy
Emmerson, Joshua T., Lauren K. Murray, and N. Jadavji. “Impact of Dietary Supplementation of One-Carbon Metabolism on Neural Recovery.” Neural Regeneration Research (2017).


MLA   Click to copy
Emmerson, Joshua T., et al. “Impact of Dietary Supplementation of One-Carbon Metabolism on Neural Recovery.” Neural Regeneration Research, 2017.


BibTeX   Click to copy

@article{joshua2017a,
  title = {Impact of dietary supplementation of one-carbon metabolism on neural recovery},
  year = {2017},
  journal = {Neural Regeneration Research},
  author = {Emmerson, Joshua T. and Murray, Lauren K. and Jadavji, N.}
}

Abstract

In the cell, one-carbon metabolism modulates nucleotide synthesis, DNA repair, as well as methylation through the reduction of homocysteine (Figure 1). High levels of plasma homocysteine have been associated with negative health outcomes in humans (Murray et al., 2017). Folates, B-vitamins, are a major component of one-carbon metabolism and play an important role in brain function. Specifically, they are involved in nucleotide synthesis, DNA repair, methylation, second messenger systems, ion channels, protein, and neurotransmitter synthesis, as well as the metabolism of homocysteine (Murray et al., 2017). Folate is the natural form found in foods, whereas folic acid is the chemically synthesized and often found in supplements. In 1998, the importance of folates was noted in the prevention of neural tube defects by both the Canadian and US governments and mandatory folic acid fortification laws were put into place. The neuroprotective properties of folic acid during development suggest that it may modulate growth and differentiation in the brain. Another component of one-carbon metabolism is the nutrient choline. In the brain, choline’s primary role is in the synthesis of the neurotransmitter, acetylcholine, and lipid metabolism. In the rest of the body, choline also generates a methyl group to remethylate homocysteine to methionine. This reaction is done to a lesser extent in the brain. Dietary supplementation using components of one-carbon metabolism in patients diagnosed with different neurological diseases might be effective in managing symptoms or reducing disease progression. A study published in 2010 reported that B-vitamin supplementation for 2 years reduced brain atrophy in patients with mild cognitive impairment within the UK (Smith et al., 2010). More recently, a clinical study in China showed that hypertensive patients treated with Enalapril and folic acid for 4.5 years had a reduced risk of developing a stroke compared to those treated with enalapril alone (Huo et al., 2015). Both these studies were conducted in countries that do not have mandatory folic acid fortification laws in place. It is important to note that not all individuals benefit from mandatory folic acid fortification. For example, individuals with a polymorphism in methylenetetrahydrofolate reductase (MTHFR) cannot reduce folic acid as effectively as someone without the polymorphism and therefore have increased levels of homocysteine. Interestingly, there are alternative ways to reduce homocysteine levels. For example, cytidine 5′-diphosphocholine (CDP-choline), a metabolite of choline, has been reported to aid in neural repair in the central and peripheral nervous systems as well as increase levels of acetylcholine (Arenth et al., 2011). The mechanisms through which one-carbon supplementation may change the brain to reduce disease severity are not well understood. We recently reported that supplementation with components of one-carbon metabolism after ischemic damage to the sensorimotor cortex increased neuroplasticity and anti-oxidant activity at the damage site as well as reduced sensorimotor impairment in a mouse model (Jadavji et al., 2017). The mice in our study were maintained on a folic acid deficient diet prior to damage to increase levels of plasma homocysteine. After ischemic damage via photothrombosis we supplemented the diet of these mice with folic acid, vitamins B12, B2, and choline for 4 weeks after which motor function of animals was assessed and tissue and blood was collected. In the supplemented mice, we observed reduced impairment on the accelerating rotarod and ladder beam task, as well as increased use of impaired forelimb on cylinder task after ischemic damage. These behavioral changes were mirrored with increases in neuronal brain derived neurotrophic factor (BDNF) and immediate early gene, FosB, levels, as well as increased phospho-AKT (pAKT) expression within the damage cortex. We also reported reduced p53 levels in supplemented mice. Additionally, both stroke and increased levels of homocysteine result in oxidative stress, so we evaluated the impact of one-carbon metabolism on antioxidant activity. We observe increased levels of nuclear factor erythroid 2-related factor 2 (Nrf2) and superoxide dismutase 2 (SOD2) at the damage site. The results from this study show that supplementation with one-carbon metabolism may be beneficial for recovery. Damage to the spinal cord allows for detailed analysis of neuronal regeneration and dissection of potential mechanisms. The impact of folic acid on regeneration was shown in a study by Iskander et al. (2004). Adult rats underwent damage to the spinal cord using the spinal cord regeneration model. Three days prior to and after damage animals were administered folic acid. The study reported a daily dose of 80 μg/kg resulted in 54 labeled neurons per ganglion which was similar to regenerating axons on the ipsilateral side to peripheral nerve injury in untreated mice. Using the Basso, Beattie, and Breshahan (BBB) scoring system, neurological recovery was assessed in the animals with spinal cord injury. Folic acid treatment produced significant improvement in the BBB starting at 7 days after injury and was maintained throughout the study period (42 days after injury). Additionally, folic acid supplementation after optic nerve injury increased the number of retinal ganglion cells (RGCs) per retina to 1,373 ± 73.42 compared to controls 913.4 ± 11.83. Another study from the same group reports that increased expression of the folate receptor 1 (Folr1) enables increased folic acid to enter the cell which then leads to positive benefits. Additionally, folic acid regulates Folr1 activation in a dose-dependent fashion (Iskandar et al., 2010). The interaction of folic acid and Folr1 is governed by dehydrate folate reductase (DHFR) and de novo methylation (Figure 1). Recent research demonstrates a strong rationale to investigate one-carbon supplementation as an epigenetic therapeutic to counteract neurodegenerative disease including Alzheimer’s disease (AD). In primary neuronal cells cultured with amyloid beta (Aβ) oligomers, cell viability and methylation status increased when folic acid was present in the media (Li et al., 2015). Methylation status in the 40 μM folic acid treatment group showed activity similar with controls including an increase in S-adenosylmethionine (SAM): S-adenosylhomocysteine (SAH) ratio, as well as reduced mRNA and protein expression of amyloid precursor protein (APP) and Presenilin-1 (PS-1) to levels observed at baseline. In vivo, 7-monthold APP/PS1 (APPswe/PS1dE9) mice supplemented with 600 μg/ kg folic acid showed consistently lower expression of APP, PS1, and Aβ (Li et al., 2015). SAM only treatment did not alter PS-1 nor Aβ expression of mRNA or proteins in brain tissue of mice. Whereas, a combined treatment of folic acid and SAM had a similar effect as only the folic acid treatment, highlighting the key role of folic acid. Increased methylation status for both the APP and PS1 genes in the